阿司匹林心血管疾病一级预防争议与共识  

Controversy and consensus on aspirin for the primary prevention of cardiovascular disease

作　　者：周晓芳[1] 

机构地区：[1]四川省医学科学院·四川省人民医院老年心血管内科,成都610072

出　　处：《中华老年医学杂志》2017年第11期1261-1266,共6页Chinese Journal of Geriatrics

摘　　要：一级预防对于降低心血管疾病发病率和病死率至关重要。阿司匹林作为心血管疾病一级预防的重要干预手段，既往多项研究已经证实了其在心血管疾病一级预防中的作用，并且是经济有效的干预措施。然而近年研究阴性结果的发布对阿司匹林一级预防提出了质疑，多重因素的共同影响导致了研究结果的差异，临床中应该加强适宜人群的规范化使用，使一级预防的临床获益最大化。Primary prevention is essential to reduction in the morbidity and mortality of cardiovascular disease. Aspirin is one of the important intervention measures for the primary prevention of cardiovascular disease and is cost-effective, and its role has been well confirmed in previous studies. However,the release of negative results in recent years has raised questions about its value for primary prevention. The combined effects of multiple factors have led to discrepancies in different studies. Standardized use of aspirin in qualified population groups for primary intervention in clinical practice should be promoted so that maximum clinical benefits can be achieved.

关 键 词：心血管疾病 阿司匹林 一级预防 

分 类 号：R54[医药卫生—心血管疾病]